Inventor
Shiro Shibayama
Inventor
Tsukuba, JP
Overview
Patents· 47 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations26%
A61KPreparations for medical, dental or toiletry purposes21%
C07DHeterocyclic compounds14%
C07KPeptides14%
Y02ATechnologies for adaptation to climate change6%
G01NInvestigating or analysing materials by determining their chemical or physical properties5%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms5%
C12NMicroorganisms or enzymes4%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture3%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%
PatentTitleYear
11,091,550Bispecific antibody202110,647,770Therapeutic agent for autoimmune diseases comprising PD-1 agonist20209,783,609'Substance specific to human PD-1'20179,701,749'Therapeutic agent for autoimmune diseases comprising PD-1 agonist'20179,439,962'Immunopotentiative composition'20169,402,899'Immunopotentiative composition'20169,393,301'Immunopotentiative composition'20169,073,994'Immunopotentiative composition'20159,067,999'Immunopotentiative composition'20158,951,518'Substance specific to human PD-1'20158,871,210'Chemokine receptor antagonists and use thereof'20148,822,459'Compound containing basic group and use thereof'20148,728,474'Immunopotentiative composition'20148,680,092'Nitrogenous heterocyclic compound and medicinal use thereof'20148,618,122'Compound having acidic group which may be protected, and use thereof'20138,614,323'Chemokine receptor antagonists and use thereof'20138,604,207'Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient'20138,574,872'Multimer of extracellular domain of cell surface functional molecule'20138,519,124'Chemokine receptor antagonists and use thereof'20138,476,290'Compound having spiro-bonded cyclic group and use thereof'20138,460,886'Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers'20138,410,276'Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient'20138,318,931'Chemokine receptor antagonists and use thereof'20128,293,896'Chemokine receptor antagonists and use thereof'20128,246,955'Substance specific to human PD-1'20128,216,996'Multimer of extracellular domain of cell surface functional molecule'20128,168,783'Chemokine receptor antagonists and use thereof'20128,168,179'Treatment method using anti-PD-L1 antibody'20128,153,625'Nitrogen-containing heterocyclic compounds and medicinal use thereof'20128,143,404'Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient'20128,003,642'Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient'20117,998,479'Substance specific to human PD-1'20117,951,816'Compound containing basic group and use thereof'20117,910,741'Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient'20117,858,746'Substance that specifically recognizes PD-1'20107,759,336'Nitrogen-containing heterocyclic compounds and medicinal use thereof'20107,732,442'Chemokine receptor antagonist and medical use thereof'20107,638,281'Polypeptide, cDNA encoding the same and use of them'20097,595,048'Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1'20097,563,869'Substance specific to human PD-1'20097,498,323'Spiro-piperidine compounds and medicinal use thereof'20097,285,552'Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient'20077,262,193'Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient'20077,189,546'Polypeptide, cDNA encoding the same, and use of them'20077,119,091'Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient'20067,053,090'Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient'20066,664,383'Polypeptides, cDNA encoding the same and utilization thereof'2003Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2003–2021Patents assigned to ONO PHARMACEUTICAL CO (46)· patent assignee history
2003–2017Based in Osaka, JP· patent location history
2006–2014Based in Mishima-shi, JP· patent location history
2009–2017Patents assigned to HONJO TASUKU (10)· patent assignee history
2009–2020Based in Tsukuba, JP· patent location history
2011–2021Based in Ibaraki, JP· patent location history
2012–2017Patents assigned to SHIBAYAMA SHIRO (19)· patent assignee history
2012–2014Patents assigned to TAKAOKA YOSHIKAZU (8)· patent assignee history
2012–2014Patents assigned to KOKUBO MASAYA (7)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ONO PHARMACEUTICAL CO | 46 | 2003–2021 |
| SHIBAYAMA SHIROself | 19 | 2012–2017 |
| HONJO TASUKU | 10 | 2009–2017 |
| TAKAOKA YOSHIKAZU | 8 | 2012–2014 |
| KOKUBO MASAYA | 7 | 2012–2014 |
Locations
| Location | Patents | Span |
|---|---|---|
| Tsukuba, JP | 23 | 2009–2020 |
| Ibaraki, JP | 10 | 2011–2021 |
| Mishima-shi, JP | 8 | 2006–2014 |
| Osaka, JP | 6 | 2003–2017 |